← Back to Home

Targeting B7-H3 and IL-8, University of Colorado Colorectal Cancer CAR-T Trial Gets FDA Clearance

Seeking another option for patients whose standard treatments have failed, researchers will bring a cell therapy targeting two pathways into human testing. Its safety and anticancer effects remain unproven, and two announcements offer different estimates for when the trial will begin.

By SURL BioNews

When advanced colorectal cancer no longer responds durably to standard treatment, patients need more scientifically grounded options. The University of Colorado Anschutz Medical Campus (CU Anschutz) announced in September that its experimental CAR-T cell therapy had received clearance from the U.S. Food and Drug Administration (FDA) to proceed to a clinical trial. The study will evaluate whether a strategy targeting both B7-H3 and IL-8-related pathways can safely exert anticancer effects in humans.

The trial is led by Christopher Lieu, a medical oncologist at the university’s cancer center. Adult participants will be patients with advanced colorectal cancer whose standard treatments have failed; the university’s initial announcement also included children with solid tumors who have exhausted standard treatment options. This regulatory milestone allows the research to enter human testing. It does not mean the therapy has been approved for marketing or that its efficacy has been established.

CAR-T therapy involves collecting a patient’s own T cells, genetically modifying them to recognize cancer, expanding them outside the body, and infusing them back into the patient. These therapies have shown results in some leukemias and lymphomas, but solid tumors are more difficult to treat. One challenge is finding targets that are highly expressed on cancer cells but less common in healthy tissues, balancing the ability to attack cancer with safety.

The team selected B7-H3, a protein found in most colorectal tumors; IL-8 is associated with inflammation, tumor growth, and spread. The researchers hope that incorporating both pathways into the design will improve the engineered T cells’ chances of overcoming tumor defenses. However, the public announcements have not detailed how the therapy intervenes in the IL-8 pathway, so it should not currently be interpreted as a dual-target CAR construct that recognizes two tumor surface antigens.

Moving from the laboratory to patients also requires reliable cell manufacturing capabilities. A follow-up report published by the university on September 21 said its Gates Biomanufacturing Facility would manufacture the therapy, while philanthropic donations would support the research. The patient featured in that report received treatment in a separate, industry-sponsored CAR-T trial targeting GCC; that patient’s treatment experience cannot serve as clinical evidence for this B7-H3 and IL-8 therapy.

The two sources have yet to align on when the trial will open. The university’s September 10 and 21 announcements both anticipated a December 2026 launch; the Colorectal Cancer Alliance wrote on September 22 that the trial was expected to open in January or February 2027. The later timeline indicates that the actual start date still awaits confirmation from the research team. These announcements do not establish that enrollment has begun.

For patients, the significance of this development is that a new strategy will finally have an opportunity to be tested in humans. The available announcements have not provided human response rates, duration of response, or adverse event data for this therapy. Whether it can deliver durable disease control, and whether it affects healthy tissues while attacking tumors, must be answered by the upcoming clinical research.

References

  1. University of Colorado Anschutz
  2. Colorectal Cancer Alliance
  3. University of Colorado Anschutz